Huang Aji, Cao Shousong, Tang Lili
Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Laboratory of Cancer Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
J Cancer. 2017 Jul 3;8(10):1884-1891. doi: 10.7150/jca.17595. eCollection 2017.
Inflammatory breast cancer (IBC) is a rare and very aggressive subtype of breast cancer with clinical manifestations similar to acute inflammation. The prognosis of IBC is still poor even though combination therapy with surgery, chemotherapy, and target therapy, mainly due to a lack of fully understanding of the cellular and molecular mechanisms of IBC pathogenesis and progression. In the present article, we have comprehensively reviewed the connection of the pathogenesis of IBC and inflammation, immune reaction and cancer, particularly focused on the role and mechanism of tumor microenvironment related to IBC formation, tumor cell proliferation, migration, invasion and metastasis as well as the clinical manifestations of IBC. As the diverse cells including inflammatory cells, immune cells, and tumor cells and the soluble molecules produced by these cells in the microenvironment play an essential role in IBC development and progression. Therefore, anti-inflammatory therapy and immunotherapy with available agents warrant further investigation in the treatment of IBC.
炎性乳腺癌(IBC)是一种罕见且侵袭性很强的乳腺癌亚型,其临床表现类似于急性炎症。尽管采用了手术、化疗和靶向治疗的联合疗法,但IBC的预后仍然很差,主要原因是对IBC发病机制和进展的细胞及分子机制缺乏全面了解。在本文中,我们全面综述了IBC发病机制与炎症、免疫反应和癌症之间的联系,特别关注了肿瘤微环境与IBC形成、肿瘤细胞增殖、迁移、侵袭和转移以及IBC临床表现相关的作用和机制。由于包括炎性细胞、免疫细胞和肿瘤细胞在内的多种细胞以及这些细胞在微环境中产生的可溶性分子在IBC的发生发展中起着至关重要的作用。因此,使用现有药物进行抗炎治疗和免疫治疗在IBC治疗中值得进一步研究。